Program
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01
Its studies are mostly in Colorectal Neoplasms, led by Radiopharm Theranostics.
Furthest: phase 2, since Sep 11, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Radiopharm Theranostics | 11 open or running | phase 2since Sep 11, 2025 | Sep 11, 2025 | Dec 2027phase 2 · NCT07189871 |
Also a collaborator on its studies: Medpace.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2025First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07189871 · 61 planned · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07189871
TargetBeta
CD276 →read by rule
“A radioimmunoconjugate consisting of a monoclonal antibody directed against the 4Ig isoform of the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276) ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07189871Colorectal Neoplasms · United States | 2 | Recruiting | Dec 2027 | 61 |
How it is read
Names in the registry
- “177Lu-BetaBart”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.